MEA Sepsis Diagnostics Market

MEA Sepsis Diagnostics Market Size (2022 to 2027)

The size of the Middle East and Africa sepsis diagnostics market was worth USD 35.36 Million in 2022 and USD 52.05 Million by 2027, growing at a CAGR of 8.04% from 2022 to 2027.

A few of the factors accelerating the growth of the Middle East and Africa (MEA) sepsis diagnostic market are the increased prevalence of sepsis, the increased incidence of hospital-acquired infections, the increased number of cases of pneumonia, the increased number of septic surgeries, and research activities related to sepsis. Nosocomial infections (HAIs) are the most common complication among inpatients, producing an estimated 4.5 HAIs per 100 inpatients and costing $ 35-45 billion annually. These HAIs are also called nosocomial infections. According to the Centers for Disease Control and Prevention (CDC), nosocomial infections can occur in 1 in 20 treated patients. Nosocomial infections cause more than 99,000 deaths each year. The most common causes of nosocomial diseases include surgical, respiratory, urinary tract, and bloodstream infections. Healthcare providers, nursing teams, and individual physicians and nurses are also aware of infection-related issues and have taken specific steps to prevent them. Similar hospital infections have been observed around the world, increasing the demand for sepsis diagnosis. As a result, increased nosocomial infections are supposed to drive the overall growth of the sepsis diagnostics market in the MEA over the forecast period.

However, the lack of awareness and the skilled workforce in the Middle East and Africa region are some factors that restrain the growth of the sepsis diagnostic market in the area.

One disadvantage of this approach is that it cannot identify organisms that cannot be cultured. Also, after blood culture, molecular diagnostic techniques are considered standard pathogen identification techniques.

This research report segmented and sub-segmented the Asia Pacific Sepsis Diagnostics Market into the following categories:

By Pathogen:

• Bacterial Sepsis    
  • Gram-Negative Bacterial Sepsis
  • Gram-Positive Bacterial Sepsis
• Fungal Sepsis        
• Other Pathogen Infections

By Product:

• Instruments          
• Blood Culture Media          
• Assay Kits & Reagents       
• Software  

By Technology:

• Microbiology         
• Molecular Diagnostics       
• Immunoassays    
• Flow Cytometry  
• Other Technologies

By Method:

• Conventional Diagnostics
• Automated Diagnostics

By Usability:

• Laboratory Testing              
• Point-of-Care Testing

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The regional market is growing due to the growing elderly population in the region, the development of healthcare infrastructure, and increasing cancer and diabetes in countries such as UAE, Saudi Arabia, South Africa, and others. In addition, MEA Sepsis Diagnostics Market is emerging with economies that offer growth opportunities due to increased neonatal umbilical cord infections and the number of surgical procedures in this region. The newly developed test uses microelectrodes to analyze a patient's blood and achieve a final result in two and a half minutes. By developing and starting this advanced rapid test, critical players in the market have ample opportunities to strengthen their position in the local market.

KEY MARKET PLAYERS:

A few of the promising companies operating in the MEA sepsis diagnostics market profiled in the report are Biomérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.